7 Results for "

hNav1.3

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "hNav1.3" in MCE Product Catalog:

  • Isoforms Recommended:
Cat. No.: HY-107405
CAS No.: 1211866-85-1
Purity:  99.67%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

TC-N 1752 is a potent and orally active inhibitor of Nav1.7, with IC50s of 0.17 μM, 0.3 μM, 0.4 μM, 1.1 μM and 2.2 μM at hNav1.7, hNav1.3, hNav1.4, hNaV1.5 and rNav1.8, respectively. TC-N 1752 also inhibits tetrodotoxin-sensitive sodium channels. TC-N 1752 shows analgesic efficacy in the Formalin model of pain .
loading...
    loading...
Cat. No.: HY-P5152
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Scorpion toxin Tf2 is a selective human voltage-gated sodium channel Nav1.3 (hNav1.3) activator. Scorpion toxin Tf2 selectively shifts the channel's activation voltage to more negative values, enabling channel opening at resting membrane potentials. Scorpion toxin Tf2 can be used for the research of epilepsy, nociception (after spinal cord injury) .
loading...
    loading...
Cat. No.: HY-P5183
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Hm1a is a venom peptide and a selective hNaV1.1 activator with an EC50 of 7.5 nM. Hm1a enhances hNaV1.1 and hNaV1.3 channel currents via delayed inactivation. Hm1a restores action potential firing in Dravet syndrome GABAergic inhibitory interneurons, reduces interictal epileptiform discharges and whole-brain hyperexcitability, lowers seizure frequency, and rescues premature death in Dravet syndrome mice. Hm1a can be used for the research of neurological disease, such as Dravet syndrome .
loading...
    loading...
Cat. No.: HY-126291
CAS No.: 2349371-81-7
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype selective Nav1.7 inhibitor (Ki of 0.79 nM and Kd of 0.38 nM for hNav1.7) for the treatment of chronic pain. GNE-616 shows >1000 nM Kd and >2500-fold selectivity over hNav1.1, hNav1.3, hNav1.4, and hNav1.5. Selectivity over hNav1.2 and hNav1.6 is more modest at 31- and 73-fold, respectively .
loading...
    loading...
Cat. No.: HY-P5916
Synonyms: κ-Theraphotoxin-Gr4a; Kappa-TRTX-Gr4a; Voltage sensor toxin 3; Peptide F
Research Areas:  

Neurological Disease

VSTx-3 is a KV channel blocker. VSTx-3 is demonstrated to be a potent, TTX-sensitive sodium channel blocker and especially, a potent blocker of NaV1.8 channels (IC50 0.19 μM for hNaV1.3, 0.43 μM for hNaV1.7 and 0.77 μM for hNaV1.8 channels).
loading...
    loading...
Cat. No.: HY-P5900
Synonyms: m3-HwTx-IV
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

m3-Huwentoxin IV (m3-HwTx-IV) is a potent NaV inhibitor with IC50s of 3.3, 6.8, 7.2, 8.4, 11.9 and 369 nM against hNaV1.7, hNaV1.6, hNaV1.3, hNaV1.1, hNaV1.2 and hNaV1.4, respectively in QPatch assay. m3-Huwentoxin IV dose-dependently suppresses spontaneous pain induced by the NaV1.7 activator OD1 in a rodent pain model .
loading...
    loading...
Cat. No.: HY-107405R
CAS No.: 1211866-85-1
Research Areas:  

Neurological Disease

TC-N 1752 (Standard) is the analytical standard of TC-N 1752 (HY-107405). This product is intended for research and analytical applications. TC-N 1752 is a potent and orally active inhibitor of Nav1.7, with IC50s of 0.17 μM, 0.3 μM, 0.4 μM, 1.1 μM and 2.2 μM at hNav1.7, hNav1.3, hNav1.4, hNaV1.5 and rNav1.8, respectively. TC-N 1752 also inhibits tetrodotoxin-sensitive sodium channels. TC-N 1752 shows analgesic efficacy in the Formalin model of pain .
loading...
    loading...